Printer Friendly

Research and Markets: Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/99tm7g/aplastic_anemia_th) has announced the addition of GlobalData's new report "Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.

GlobalData, the industry analysis specialist, has released its new report, Aplastic Anemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global aplastic anemia therapeutics market. The report identifies the key trends shaping and driving the global aplastic anemia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global aplastic anemia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Aplastic Anemia Market is Forecast to Show Slow Growth until 2019

GlobalData estimates that the global aplastic anemia therapeutics market was worth $73.3m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.1% to reach $79.7m by 2019. The current treatment options for aplastic anemia include allogeneic stem cell transplant and immunosuppressive therapy which are primarily dominated by generics. There is no promising, industry-sponsored molecule in the late stage pipeline. Owing to these factors, the aplastic anemia market is expected to show slow growth until 2019.

The Aplastic Anemia Market has Moderate Unmet Need

Current treatment options for aplastic anemia are allogeneic stem cell transplant or immunosuppressive therapy. Although these therapies are effective in approximately 70% of patients, stem cell transplant is associated with the risk of developing graft failure and graft-versus-host disease (GVHD). Chances of relapse and further development to myelodysplastic syndrome (MDS) limit the use of immunosuppressive therapy. Therefore, a moderate unmet need exists in the treatment of aplastic anemia.

Companies Mentioned

- Bellicum Pharmaceuticals, Inc

For more information visit http://www.researchandmarkets.com/research/99tm7g/aplastic_anemia_th

Source: GlobalData
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 28, 2012
Words:397
Previous Article:Research and Markets: Hong Kong Retail Report Q3 2012.
Next Article:Research and Markets: Introduction to Chemical Transport in the Environment.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters